Market open
Precision BioSciences/$DTIL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Precision BioSciences
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Ticker
$DTIL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
108
Website
DTIL Metrics
BasicAdvanced
$55M
5.03
$1.04
1.58
-
Price and volume
Market cap
$55M
Beta
1.58
52-week high
$13.44
52-week low
$3.61
Average daily volume
204K
Financial strength
Current ratio
6.341
Quick ratio
5.875
Long term debt to equity
50.937
Total debt to equity
53.278
Interest coverage (TTM)
-14.68%
Management effectiveness
Return on assets (TTM)
-11.04%
Return on equity (TTM)
19.05%
Valuation
Price to earnings (TTM)
5.029
Price to revenue (TTM)
0.52
Price to book
0.76
Price to tangible book (TTM)
0.77
Price to free cash flow (TTM)
-0.609
Growth
Revenue change (TTM)
40.98%
Earnings per share change (TTM)
-106.52%
3-year revenue growth (CAGR)
-15.91%
3-year earnings per share growth (CAGR)
-59.49%
What the Analysts think about DTIL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Precision BioSciences stock.
DTIL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
DTIL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
DTIL News
AllArticlesVideos
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
Business Wire·2 weeks ago
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
Business Wire·4 weeks ago
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Precision BioSciences stock?
Precision BioSciences (DTIL) has a market cap of $55M as of April 30, 2025.
What is the P/E ratio for Precision BioSciences stock?
The price to earnings (P/E) ratio for Precision BioSciences (DTIL) stock is 5.03 as of April 30, 2025.
Does Precision BioSciences stock pay dividends?
No, Precision BioSciences (DTIL) stock does not pay dividends to its shareholders as of April 30, 2025.
When is the next Precision BioSciences dividend payment date?
Precision BioSciences (DTIL) stock does not pay dividends to its shareholders.
What is the beta indicator for Precision BioSciences?
Precision BioSciences (DTIL) has a beta rating of 1.58. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.